Core Insights - Axalta Coating Systems reported revenue of $1.31 billion for the quarter ended June 2025, a decrease of 3.4% year-over-year, with EPS at $0.64, up from $0.57 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $1.32 billion, resulting in a surprise of -1.33%, while the EPS exceeded the consensus estimate of $0.61 by 4.92% [1] Financial Performance - Total sales in Performance Coatings were $836 million, below the average estimate of $872.1 million, reflecting a year-over-year decline of 5.8% [4] - Total sales in Mobility Coatings reached $469 million, slightly above the average estimate of $463.08 million, marking a year-over-year increase of 1.1% [4] - Sales in Mobility Coatings for commercial vehicles were $107 million, compared to an estimate of $100.02 million, showing a decline of 2.7% year-over-year [4] - Sales in Performance Coatings for industrial applications were $322 million, below the average estimate of $327.45 million, representing a year-over-year decrease of 5.6% [4] - Sales in Mobility Coatings for light vehicles were $362 million, slightly below the estimate of $363.06 million, with a year-over-year increase of 2.3% [4] - Sales in Performance Coatings for refinish applications were $514 million, below the average estimate of $544.4 million, reflecting a year-over-year decline of 5.9% [4] - Adjusted EBIT for Mobility Coatings was $92 million, exceeding the estimate of $74.79 million [4] - Adjusted EBIT for Performance Coatings was $200 million, below the average estimate of $209.59 million [4] Market Performance - Axalta Coating Systems' shares have returned -5.9% over the past month, contrasting with the Zacks S&P 500 composite's increase of 3.4% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Group 1 - CRISPR Therapeutics AG (CRSP) has an average brokerage recommendation (ABR) of 1.88, indicating a consensus between Strong Buy and Buy based on 27 brokerage firms' recommendations [2][5] - Out of the 27 recommendations, 15 are classified as Strong Buy, accounting for 55.6%, while one is classified as Buy, accounting for 3.7% [2] - Despite the positive ABR, reliance solely on brokerage recommendations may not be advisable, as studies suggest they often fail to guide investors effectively towards stocks with high price appreciation potential [5][10] Group 2 - Brokerage analysts tend to exhibit a strong positive bias in their ratings due to vested interests, often resulting in a disproportionate number of Strong Buy recommendations compared to Strong Sell [6][10] - The Zacks Rank, a proprietary stock rating tool, is presented in whole numbers and is based on earnings estimate revisions, which have shown a strong correlation with near-term stock price movements [8][11] - The Zacks Consensus Estimate for CRISPR Therapeutics has declined by 1.4% over the past month to -$5.61, indicating growing pessimism among analysts regarding the company's earnings prospects [14][15] Group 3 - The recent change in the consensus estimate, along with other earnings-related factors, has led to a Zacks Rank of 4 (Sell) for CRISPR Therapeutics, suggesting caution despite the favorable ABR [15] - The ABR may not always reflect the most current information, while the Zacks Rank is updated more frequently to reflect changes in earnings estimates [13]

Check price target & stock forecast for Archrock Inc. here>>> When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these Wall Street heavyweights have to say about Archrock Inc. (AROC) before we discuss the reliability of brokerage recommendations and how to use them to your advan ...

Core Viewpoint - RE/MAX reported a decline in revenue and earnings for the quarter ended June 2025, indicating potential challenges in financial performance compared to previous periods and market expectations [1][3]. Financial Performance - Revenue for the quarter was $72.75 million, down 7.3% year-over-year, and below the Zacks Consensus Estimate of $73.47 million by 0.98% [1]. - Earnings per share (EPS) were $0.39, a decrease from $0.41 in the same quarter last year, but exceeded the consensus estimate of $0.35 by 11.43% [1]. Key Metrics - Marketing Funds fees revenue was $18.27 million, slightly above the average estimate of $18 million, but down 8.8% year-over-year [4]. - Continuing franchise fees revenue was $28.99 million, below the average estimate of $29.32 million, reflecting a 4.4% decline year-over-year [4]. - Franchise sales and other revenue totaled $4.34 million, significantly lower than the $4.87 million average estimate, marking a 19.8% decrease year-over-year [4]. - Broker fees revenue was $13.45 million, slightly above the average estimate of $13.39 million, with a year-over-year decline of 7.4% [4]. - Annual dues revenue was $7.69 million, below the estimated $7.85 million, representing a 5.6% decrease compared to the previous year [4]. Stock Performance - Over the past month, RE/MAX shares returned +0.1%, underperforming the Zacks S&P 500 composite's +3.6% change [3]. - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3].

Core Viewpoint - The average brokerage recommendation (ABR) for Diebold Nixdorf, Incorporated (DBD) is 1.00, indicating a Strong Buy based on recommendations from three brokerage firms, all of which are Strong Buy [2][5] Brokerage Recommendation Trends - The current ABR of 1.00 is derived from three Strong Buy recommendations, representing 100% of all recommendations [2] - Despite the Strong Buy recommendation, reliance solely on brokerage recommendations may not be wise, as studies show limited success in guiding investors to stocks with the best price increase potential [5][10] Zacks Rank and Its Importance - Zacks Rank categorizes stocks into five groups, from Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell), and is based on earnings estimate revisions, which correlate strongly with near-term stock price movements [8][11] - The Zacks Rank is distinct from ABR, as it is a quantitative model that reflects timely earnings estimate revisions, while ABR may not be up-to-date [9][13] Current Earnings Estimates for DBD - The Zacks Consensus Estimate for Diebold Nixdorf, Incorporated remains unchanged at $3.57 for the current year, indicating steady analyst views on the company's earnings prospects [14] - The unchanged consensus estimate has resulted in a Zacks Rank 3 (Hold) for Diebold Nixdorf, suggesting caution despite the Buy-equivalent ABR [15]

Core Insights - First Financial Bancorp (FFBC) reported revenue of $227.58 million for the quarter ended June 2025, reflecting a year-over-year increase of 5.3% [1] - Earnings per share (EPS) for the quarter was $0.74, up from $0.65 in the same quarter last year, surpassing the consensus estimate of $0.69 by 7.25% [1] - The reported revenue exceeded the Zacks Consensus Estimate of $219.8 million, resulting in a revenue surprise of 3.54% [1] Financial Metrics - Net Interest Margin was reported at 4%, matching the average estimate from two analysts [4] - Efficiency Ratio stood at 56.9%, better than the average estimate of 57.6% from two analysts [4] - Total Noninterest Income reached $68.06 million, exceeding the average estimate of $64.6 million from two analysts [4] Stock Performance - Over the past month, shares of First Financial have returned +1%, while the Zacks S&P 500 composite has increased by +5.7% [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), indicating potential for outperformance against the broader market in the near term [3]

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about Sterling Infrastructure (STRL) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Sterling Infrastructure cur ...

Core Viewpoint - Norfolk Southern (NSC) is expected to report quarterly earnings of $3.26 per share, a 6.5% increase year-over-year, with revenues projected at $3.13 billion, reflecting a 2.9% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 2.2% over the past 30 days, indicating a reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock performance [3]. Revenue Projections - Analysts estimate 'Railway operating revenues - Merchandise - Agriculture, forest and consumer products' will reach $643.81 million, a year-over-year increase of 3.5% [5]. - 'Railway operating revenues - Coal' is expected to be $396.48 million, showing a slight decline of 0.4% [5]. - 'Railway operating revenues - Merchandise - Chemicals' is projected at $549.39 million, reflecting a 3.3% increase [6]. - 'Railway operating revenues - Intermodal' is forecasted to reach $765.09 million, indicating a 3.1% increase [6]. Volume Estimates - Total carloads (units) are expected to reach 1.81 million, up from 1.74 million year-over-year [7]. - Coal carloads are estimated at 176.35 thousand, compared to 162.90 thousand from the previous year [7]. - The 'Railway Operating Ratio' is projected to be 62.5%, slightly improving from 62.8% year-over-year [7]. Specific Merchandise Volume - 'Carloads (Units) - Volume - Merchandise - Agriculture, forest and consumer products' is estimated at 185.49 thousand, up from 181.20 thousand [8]. - 'Carloads (Units) - Volume - Merchandise - Automotive' is projected at 99.12 thousand, compared to 97.20 thousand last year [8]. - 'Carloads (Units) - Volume - Merchandise - Metals and construction' is expected to be 170.11 thousand, up from 167.90 thousand [9]. - 'Carloads (Units) - Volume - Merchandise - Chemicals' is estimated at 132.78 thousand, compared to 130.10 thousand last year [9]. Revenue per Carload - Revenue per carload (unit) for Intermodal is forecasted to be $735.20, slightly down from $739.00 in the same quarter last year [10]. Stock Performance - Norfolk Southern shares have increased by 9.8% over the past month, outperforming the Zacks S&P 500 composite, which rose by 5.7% [11].

Group 1: Earnings and Revenue Forecasts - Booking Holdings (BKNG) is expected to report quarterly earnings of $50.46 per share, reflecting a 20.4% increase year over year [1] - Analysts forecast revenues of $6.56 billion, indicating an 11.9% year-over-year growth [1] - The consensus EPS estimate has been adjusted upward by 0.4% over the past 30 days, showing analysts' reassessment of projections [1] Group 2: Key Revenue Metrics - 'Revenues- Agency' is expected to be $2.03 billion, a decrease of 5.4% from the prior-year quarter [3] - 'Revenues- Advertising and Other Revenues' is projected to reach $282.45 million, an increase of 5% year over year [4] - 'Revenues- Merchant' is anticipated to be $4.25 billion, reflecting a 23.3% increase compared to the previous year [4] Group 3: Gross Bookings and Units Sold - Total 'Gross Bookings' is projected at $46.23 billion, up from $41.40 billion year over year [4] - 'Gross Bookings - Agency' is expected to be $14.62 billion, down from $15.60 billion in the prior year [5] - 'Units Sold - Room Nights' is forecasted to reach 300.87 million, compared to 287.00 million in the same quarter last year [6] Group 4: Market Performance - Over the past month, shares of Booking Holdings have returned +4.6%, while the Zacks S&P 500 composite has changed +5.7% [7] - BKNG currently holds a Zacks Rank 1 (Strong Buy), suggesting potential outperformance in the near future [7]

Group 1: Earnings Performance - RenaissanceRe reported quarterly earnings of $12.29 per share, exceeding the Zacks Consensus Estimate of $10.28 per share, but down from $12.41 per share a year ago, representing an earnings surprise of +19.55% [1] - The company posted revenues of $2.83 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 4.4% and down from $2.95 billion year-over-year [2] Group 2: Stock Performance and Outlook - RenaissanceRe shares have declined approximately 4.7% since the beginning of the year, while the S&P 500 has gained 7.3% [3] - The current consensus EPS estimate for the upcoming quarter is $4.23 on revenues of $3.05 billion, and for the current fiscal year, it is $21.41 on revenues of $12.12 billion [7] Group 3: Industry Context - The Insurance - Property and Casualty industry is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]